Article
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2014
Lim Sung Hee, Lee Ji Yun, Sun Jong-Mu, Ahn Jin Seok, Park Keunchil, Ahn Myung-Ju
Abstract excerpt
BACKGROUND: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and prolonged progression-free survival (PFS) in patients harboring an activating EGFR mutation. We compared the clinical...
Topics
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Erlotinib Hydrochloride
- Exons
- Female
- Follow-Up Studies
- Gefitinib
- Humans
- Lung Neoplasms
- Male